Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
Tirzepatide, sold as Mounjaro and Zepbound, works similarly but also targets another hormone, GIP, which may further enhance weight loss
An increase in the bodys cellular sensitivity to insulin was also observed (141)
Book a consult or reach out to us today!
Liu Y, Song Z, Liu Y, Ma X, Wang W, Ke Y, et al
Oxidative stress has been established as a cause of major depressive disorder (depression)